Birth Defects Insights: Biting Questions on this ‘World Birth Defects Day’
By Alan M. Hoberman, PhD, DABT, ATS, and Elise M. Lewis, PhD
Is the link between Zika and microcephaly real? Scientists will face an uphill battle proving cause and effect. Animal models can help.
Until a few months ago, microcephaly rarely came up in scientific discussions. Today, it’s front-page news. We’ve all seen or read the reports about microcephaly and its possible association with Zika, a virus spread by Aedes aegypti mosquitoes.
The numbers are concerning. Over 5,000 suspected cases of microcephaly have now been reported in Brazil after a major Zika outbreak surfaced in May, according to Brazilian public health authorities. Microcephaly cases have also been linked to an outbreak in French Polynesia that swept across the South Pacific island chain two years ago.
For those of us who research birth defects (in our case as reproductive and developmental toxicologists on the preclinical side) the information emerging from Brazil is confusing. For one, congenital anomalies don’t typically occur in clusters. Secondly, microcephaly has never been linked to a mosquito-borne virus until now, let alone one with a relatively benign profile.
By definition, microcephaly is a marked reduction in the size and development of the cranium and its contents. Microcephaly (Gr. mikros, small + kephale, head) is correlated with microencephaly (Gr. mikros, small + enkephalos, brain) due to the lack of pressure from the brain to expand the calvaria (i.e., skullcap) during fetal development. In humans, the most critical period of brain development is from Gestation Weeks 3 to 16, but abnormal development can still occur during the postnatal period. In the small animal models that we primarily work with, rodents and nonrodents, microcephaly does occur, but is difficult to diagnose. Numerous genetic factors and maternal exposure to hyperthermia, infectious agents such as cytomegalovirus, rubella and toxoplasma gondii, chemical agents, and high levels of irradiation during the fetal growth period have been linked to microcephaly, especially in animal models.
Its true incidence is also hard to deduce and reflective of how much debate there is on which head size actually constitutes microcephaly. Depending upon how one defines the condition, microcephaly can be as infrequent as 2 in every 10,000 births or as frequent as 12 in every 10,000 births. Microcephaly is defined by most clinicians and researchers as a head circumference (HC) of more than three standard deviations below the mean for gestational age and sex in defining microcephaly. The accuracy of the measurement can be influenced by the presence of fluid beneath the scalp and by the head shape.
Because we all have different head sizes at birth, a true microcephalic infant is difficult to diagnose. In certain instances, the head is just small without apparent developmental delays or life threatening conditions. But a baby with microcephaly may also suffer from seizures that shorten their life span, developmental delays, speech delays, hearing loss, and vision problems.
The Zika Puzzle
Even less is known about Zika, in part because its relatively benign nature has been of little interest to researchers until now. The Zika virus is related to the viruses that cause dengue, yellow fever, Japanese encephalitis, chikungunya, and West Nile. It was first recognized in the late 1940s. Until recently, it was thought to cause only mild symptoms in some cases and no symptoms in 80% of adult cases.
Given that the virus has been present in some parts of Africa for decades, one might wonder why we haven’t developed a vaccine sooner and how we let the virus, which is now evident in more than 30 countries, spiral out of control? The main reason is that Zika’s mostly mild symptoms never justified widespread vaccination. Vaccines are a great public health benefit, but they aren’t risk-free and so researchers and vaccine developers must always weigh the risk and benefits of contracting a given virus. In the case of smallpox or polio, developing a vaccine makes sense because the morbidity and mortality that occurs from contracting the virus vastly outweigh any adverse effects associated with the vaccine. Until now, Zika did not present such a public health problem.
The World Health Organization (WHO) and the US Centers for Disease Control and Prevention (CDC) have done the right thing in alerting the public about the potential health hazards of Zika infection, especially during pregnancy. In addition, the Teratology Society and MotherToBaby are taking a proactive approach to educating healthcare professionals and the general public by describing the epidemiology of the Zika virus as well as the malformations which have been proposed to be associated with Zika virus infection in pregnancy. Transmission of Zika virus seems to occur mostly via mosquitoes although the presence of the virus in semen or other body fluids may also lead to viral transmission. In either case, if it turns out that the real hazard is increased in pregnant women, then preventing infections during pregnancy may be important.
Efforts have also accelerated in recent days to develop a preventive vaccine, with the US National Institute of Allergy and Infectious Diseases’ Vaccine Research Center (VRC) leading the effort. The VRC has extensive experience working on vaccines for other mosquito-borne viruses such as West Nile virus, chikungunya virus, and dengue fever, and they developed one of the Ebola vaccine candidates that underwent clinical trials last year in Africa. Sanofi Pasteur, the vaccine division of French pharmaceutical giant Sanofi, which recently gained approval for the world’s first dengue vaccine, also just launched a project to develop a Zika vaccine.
This effort will take time, though. Nikos Vasilakis, an arbovirus researcher at University of Texas Medical Branch in Galveston and member of the Center for Biodefense and Emerging Infectious Diseases in Galveston told the BBC that it would take two years to develop a vaccine, but possibly 10 to 12 years to find one effective enough to be approved by regulators for public use.
Cause and effect
Given the high percentage of Zika infections that are probably going undetected, and the natural background incidence of microcephaly (the annual number of cases in Brazil prior to Zika), it is important now to move from association to understanding causation in order to prevent more cases of microcephaly and possibly other birth defects.
This is where basic research is needed in order to prove causation and lead us to the best ways to prevent birth defects following Zika exposure. To establish causation, researchers usually use the Bradford Hill criteria, otherwise known as Hill's criteria for causation. These are a group of minimal conditions necessary to provide adequate evidence of a causal relationship between incidence and possible consequence. They were established by the English epidemiologist Sir Austin Bradford Hill (1897–1991) in 1965.
The criteria are as follows:
Strength (effect size): A small association does not mean that there is not a causal effect, though the larger the association the more likely that it is causal.
Consistency (reproducibility) Consistent findings observed by different persons in different places with different samples strengthen the likelihood of an effect.
Specificity: Causation is likely if there is a very specific population at a specific site and disease with no other likely explanation. The more specific an association between a factor and an effect is, the bigger the probability of a causal relationship.
Temporality: The effect has to occur after the cause (and if there is an expected delay between the cause and expected effect, then the effect must occur after that delay).
Biological gradient: Greater exposure should generally lead to greater incidence of the effect. However, in some cases, the mere presence of the factor can trigger the effect. In other cases, an inverse proportion is observed: greater exposure leads to lower incidence.
Plausibility: A plausible mechanism between cause and effect is helpful (but Hill noted that knowledge of the mechanism is limited by current knowledge).
Coherence: Coherence between epidemiological and laboratory findings increases the likelihood of an effect. However, Hill noted that "... lack of such [laboratory] evidence cannot nullify the epidemiological effect on associations".
Experiment: "Occasionally it is possible to appeal to experimental evidence".
Analogy: The effect of similar factors may be considered.
For the epidemiologist the gold standard would be a randomized control study of pregnant women exposed to Zika compared to a group of unexposed matched controls. Such a study could never be ethically conducted, however, because the fetus can never consent to the test. But a case-control study of women who have given birth to babies with microcephaly, compared with a group of women with babies without microcephaly could be examined for infection with Zika. In fact, such a study is already in the works and we should hopefully have results soon.
One can also glean clues from animal studies. For instance, pregnant animals could be infected with Zika virus and the outcomes monitored for signs of microcephaly. Of course, identifying an appropriate model would be necessary and basic research with the virus would be needed to determine if Zika is active in the exposed species. While prophylactic and therapeutic vaccines have different purposes (prevention vs. treatment), the study designs to test for potential reproductive or developmental effects are generally the same. The study designs can be combined or narrowed to focus on one or more aspects of the reproductive life cycle. Testing in conventional laboratory species may be appropriate, but the expectation is that the clinical product be tested in a sensitive species. In addition, the selected species should develop an immune response similar to that elicited by humans.
If causation is established, any treatment, whether it’s a preventive vaccine or an antiviral drug, must be found to be safe and effective. Since pregnant animals would be used for both aspects of this testing, understanding the background incidence of birth defects in the animal model and understanding the effects of exposure during pregnancy are of utmost importance.
Choosing the right animal models and doing the proper safety testing is key to accelerating the development of life-saving therapies. But the Zika response is very much a work in progress. Unlike the recent Ebola crisis in West Africa, where scientists had already gleaned a lot about the biology of the virus and had a vaccine candidate in the pipeline when the outbreak struck in 2014, scientists are starting from scratch on this one. They have yet to develop a rodent or large animal model for the disease, which will be needed to study the initial efficacy of any vaccine.
These are biting questions. The world wants answers. But the long-term solutions will take time and money and a collaborative response.
The latest Zika and microcephaly guidance from the CDC and WHO may be found here:
About the Authors
Dr. Alan M. Hoberman is a 40-year veteran in toxicology who has specialized in reproductive and developmental toxicology for over 34 years. Currently, he is responsible for designing, supervising and evaluating reproductive, developmental, and juvenile toxicity studies throughout Charles River.Laboratories. He is a Diplomate of the American American Board of Toxicology, a fellow of the Academy of Toxicological Society and is the current Vice President-Elect of the Teratology Society. Dr. Hoberman has authored over 85 publications and presented 200 abstracts and lectures in the fields of reproductive and developmental toxicology, neurotoxicology, inhalation toxicology, photobiology and regulatory toxicology. This blog has also been posted on Dr. Hoberman's LinkedIn page.
Dr. Elise M. Lewis is a Study Director and Director, Reproductive and Neurobehavioral Toxicology at Charles River Laboratories’ safety and assessment site in Horsham, Pa. She has authored or co‑authored multiple publications in various areas of reproductive, developmental, and juvenile toxicology, and co-edited the first pediatric nonclinical drug testing book “Pediatric Non-Clinical Drug Testing: Principles, Requirements, and Practice.” Dr. Lewis also presents seminars and courses in animal research, toxicology and reproductive toxicology regularly for students from grade school through graduate school. Dr. Lewis is an active member of the Teratology Society, currently serving as Vice Chair of the Membership Committee.
About the Teratology Society
Scientists interested or are already involved in research related to topics mentioned in this blog are encouraged to join the Teratology Society, the premier source for cutting-edge research and authoritative information related to birth defects and developmentally-mediated disorders. Members include those specializing in cell and molecular biology, developmental biology and toxicology, reproduction and endocrinology, epidemiology, nutritional biochemistry, and genetics, as well as the clinical disciplines of prenatal medicine, pediatrics, obstetrics, neonatology, medical genetics, and teratogen risk counseling. In addition, it publishes the scientific journal, Birth Defects Research. Learn more at www.Teratology.org.
Find the Teratology Society on
About World Birth Defects Day
According to the International Clearninghouse for Birth Defects Surveillance and Research, an estimated 1 in 33 infants are affected by birth defects every year around the world, resulting in approximately 3.2 million birth defect-related disabilities. Along with more than 50 birth defects-related organizations around the world, the Teratology Society is helping to raise awareness of the important issue by participating in World Birth Defects Day. The commemorative day is observed yearly on March 3 and aims to highlight the importance of improving prevention strategies and research that will ultimately lead to a healthier society.